A Phase 1 study of PRX005
Latest Information Update: 28 Aug 2023
At a glance
- Drugs BMS 986446 (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Frontotemporal dementia; Neurodegenerative disorders
- Focus Adverse reactions; First in man
- 20 Jul 2023 Results (n=19) presented at the Alzheimer's Association International Conference 2023
- 17 Jul 2023 According to a Prothena media release, trial met primary objective of SAD portion and supporting evaluation of doses in the MAD portion.
- 17 Jul 2023 According to a Prothena media release, data from this trial presented at the Alzheimer's Association International Conference 2023 (AAIC) being held July 16-20, 2023 in Amsterdam, Netherlands and virtually.